title: Clinical impact of adjuvant chemotherapy in glioblastoma multiforme : a meta-analysis.
abstract: BACKGROUND
  A meta-analysis of chemotherapy for glioblastoma multiforme (GBM) was performed. We sought to update prior analyses by focusing exclusively on GBM, including new trials of novel treatments, assessing effectiveness of individual treatment categories and presenting data in a clinically useful format.
  
  
  METHODS
  A search of MEDLINE and EMBASE was conducted for randomised controlled trials of chemotherapy in GBM.
  
  
  RESULTS
  Relative risks (RRs) for survival in 16 trials comparing chemotherapy with no chemotherapy were 1.18 (95% CI 1.08, 1.30) at 6 months, 1.53 (95% CI 1.26, 1.86) at 12 months and 2.12 (95% CI 1.60, 2.80) at 24 months. Nitrosourea compounds, local therapy (e.g. carmustine [1,3-bis [2-chloroethyl]-1-nitrosourea] wafers) and temozolomide were all more effective than no chemotherapy. Absolute increases in survival at 6, 12 and 24 months were 11%, 8% and 1%, respectively, for nitrosourea compounds; 8%, 24% and 5%, respectively, for local therapy; and 4%, 15% and 17%, respectively, for temozolomide. Efficacy of local therapy and temozolomide peaked at 12 and 18 months, respectively. After 2 years, nitrosourea compounds no longer provided clinically relevant benefit (number needed-to-treat [NNT] = 100; effect size [ES] = 0.17 SD), local therapy had diminishing returns (NNT = 20) that remained clinically relevant (ES = 0.71 SD) and temozolomide continued to show good efficacy (NNT = 5.9; ES = 0.74 SD). Survival was not significantly improved with multi-agent versus single-agent nitrosourea-based therapy in five trials: 6-month RR 0.91 (95% CI 0.71, 1.16); 24-month RR 1.33 (95% CI 0.72, 2.46).
  
  
  CONCLUSIONS
  Although nitrosourea compounds, local therapy and temozolomide are all effective in the treatment of GBM, local therapy and temozolomide may be associated with greater response, with clinically significant benefits extending to 24 months. The timing of peak benefits of local and temozolomide therapy suggests this combination may be more effective than single-agent chemotherapy and warrants further study.
authors: VA Greater Los Angeles Healthcare System, Los Angeles, California 90073, USA. bspiegel@mednet.ucla.edu
authors: Brennan M R
authors: BM
authors: Spiegel
authors: Eric
authors: E
authors: Esrailian
authors: Loren
authors: L
authors: Laine
authors: Marc C
authors: MC
authors: Chamberlain
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D017594:Publication Bias; D016032:Randomized Controlled Trials as Topic / Q000592:standards; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents
references: Cancer. 2001 Jul 15;92(2):420-33
references: 11466698
references: J Neurooncol. 2002 Oct;60(1):53-9
references: 12416546
references: J Clin Oncol. 2001 Jan 15;19(2):509-18
references: 11208845
references: Oncology. 1996 Jan-Feb;53(1):43-6
references: 8570130
references: Int J Radiat Oncol Biol Phys. 1979 Sep;5(9):1589-92
references: 231595
references: Semin Oncol. 2003 Dec;30(6 Suppl 19):19-22
references: 14765380
references: Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9
references: 9218294
references: BMJ. 1995 Feb 18;310(6977):452-4
references: 7873954
references: Ann Intern Med. 1997 May 1;126(9):712-20
references: 9139558
references: J Clin Oncol. 2005 Apr 1;23 (10 ):2372-7
references: 15800329
references: Surg Neurol. 1987 Mar;27(3):259-63
references: 3544286
references: Clin Neurol Neurosurg. 1985;87(3):167-71
references: 2996816
references: Cancer Clin Trials. 1979 Spring;2(1):43-8
references: 229983
references: Neuro Oncol. 2003 Apr;5(2):79-88
references: 12672279
references: Cancer Res. 1998 Feb 15;58(4):672-84
references: 9485020
references: Cancer. 2003 Oct 15;98(8):1745-8
references: 14534892
references: Cancer Res. 2004 Oct 1;64(19):6892-9
references: 15466178
references: Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002092
references: 16437440
references: J Neurosurg. 1986 Jan;64(1):53-7
references: 3455717
references: Br J Cancer. 2005 Apr 25;92(8):1372-81
references: 15812554
references: Cancer. 1983 Sep 15;52(6):997-1007
references: 6349785
references: Eur J Cancer. 1991;27(5):568-71
references: 1828963
references: Tumori. 1993 Jun 30;79(3):198-201
references: 8236504
references: Cancer. 1980 Mar 15;45(6):1289-99
references: 6244079
references: Ann Surg Oncol. 2006 Mar;13(3):291-301
references: 16450219
references: Control Clin Trials. 1996 Feb;17(1):1-12
references: 8721797
references: Cochrane Database Syst Rev. 2002;(4):CD003913
references: 12519620
references: Cancer. 1993 Apr 15;71(8):2585-97
references: 8453582
references: Biometrics. 1977 Mar;33(1):159-74
references: 843571
references: J Surg Oncol. 1985 Mar;28(3):214-6
references: 2983151
references: J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6
references: 10480340
references: J Clin Oncol. 2006 Mar 10;24(8):1253-65
references: 16525180
references: Acta Neuropathol. 2005 Jan;109(1):93-108
references: 15685439
references: Semin Oncol. 2004 Oct;31(5):635-44
references: 15497116
references: Neurology. 1994 Aug;44(8):1479-83
references: 8058153
references: J Clin Oncol. 2003 Apr 15;21(8):1485-91
references: 12697871
references: N Engl J Med. 2005 Mar 10;352(10 ):987-96
references: 15758009
references: Semin Oncol. 2003 Dec;30(6 Suppl 19):15-8
references: 14765379